Em­bat­tled ge­net­ics test­ing gi­ant 23andMe is think­ing of sell­ing it­self as it runs out of cash. The com­pa­ny needs ...
Me (ME) forms special board committee to explore strategic alternatives, including sale, restructuring, or business ...
As AI advances genomic analyses, the potential for misuse grows, amplifying risks of discrimination and exploitation that could span generations. 23andMe’s struggles demonstrate that the ...
While 23andMe’s privacy statement has changed since ... publicized 23andMe data to try to find a match. And who knows what AI systems will be able to learn based on our DNA, and all the ways ...
23andMe’s shares have traded below the $1 Nasdaq ... as those interested in its consumer business or its potential for AI. A ...
The struggling genetic-testing company 23andMe has been quietly exploring a possible sale of its telehealth offering, Business Insider has learned. 23andMe has been testing the waters for a buyer ...
From cloud chaos to clarity.” In this episode, AT&T’s Erian Laperi, Kristina Sutton, and Dan Wagner discuss transforming one ...
23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses. The company that made its name by providing saliva ...
© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...
Vertical farms, woke AI, and 23andMe made our annual list of failed tech. From chatbots dishing out illegal advice to dodgy AI-generated search results, take a look back over the year’s top AI ...
23andMe's stock plummeted after a 2023 data breach exposed millions of customer accounts. The struggling genetic-testing company 23andMe has been quietly exploring a possible sale of its ...
23andMe has been exploring a possible sale of its telehealth business, Business Insider has learned. The struggling health company bought the virtual-care startup Lemonaid in 2021 for $400 million ...